Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting

Reuters02-05 20:05

<a href="https://laohu8.com/S/OCUL">Ocular Therapeutix</a> to Present Phase 3 SOL-1 Wet <a href="https://laohu8.com/S/AMD">AMD</a> Trial Results at Macula Society Meeting

Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609583372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609583372","market":"fut","top_or_hot":-1,"title":"Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> to Present Phase 3 SOL-1 Wet <a href=\"https://laohu8.com/S/AMD\">AMD</a> Trial Results at Macula Society Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> to Present Phase 3 SOL-1 Wet <a href=\"https://laohu8.com/S/AMD\">AMD</a> Trial Results at Macula Society Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL7JHQDK:1","article_id":"2609583372","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609583372","pubTimestamp":1770293159,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI  for the treatment of wet age-related macular degeneration . The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OCUL":"Ocular Therapeutix"},"translate_title":"Ocular Therapeutix将在黄斑协会会议上展示3期SOL-1湿性AMD试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":0.9},"content_text":"Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting\n    \n\n        Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609583372","isCrawlerRequest":true}